by A evaluation completed in rats implies that utilizing vitamin C might probably assist to counteract the muscle atrophy that may be a widespread facet impact of the chemotherapy drug doxorubicin. Even if medical experiences can be needed to determine the protection and effectiveness of taking vitamin C at some stage in doxorubicin remedy, the conclusions recommend vitamin C would possibly signify a promising alternative to reduce among the drug’s most debilitating facet outcomes.

Our outcomes suggest vitamin C as a possible adjunct remedy to assist within the administration of peripheral muscle issues proper after process with doxorubicin, due to this fact enhancing purposeful potential and good high quality of life-style and decreasing mortality.”


Antonio Viana do Nascimento Filho, a grasp’s pupil in medication at Faculty Nove de Julho (UNINOVE) in Brazil, preliminary author of the evaluation

Nascimento Filho will present the findings on the American Physiological Society annual meeting in the middle of the Experimental Biology (EB) 2022 convention, held in Philadelphia April 2–5.
Doxorubicin is an anthracycline chemotherapy drug that’s typically employed alongside with different chemotherapies to deal with breast most cancers, bladder most cancers, lymphoma, leukemia and numerous different most cancers varieties. Although it’s a potent anti-most cancers drug, doxorubicin can result in extreme coronary coronary heart points and muscle atrophy, with lasting impacts on survivors’ precise bodily stamina and high quality of life-style.
These facet outcomes are thought-about to finish outcome from an excessive technology of oxygen reactive species or “completely free radicals” within the physique. Vitamin C is a natural antioxidant that may assist to chop down oxidative stress, the kind of issues triggered by no value radicals.
In a previous analysis executed with the College of Manitoba in Canada, the research group recognized that vitamin C improved markers of coronary heart effectively being and survival in rats provided doxorubicin, primarily by lessening oxidative stress and swelling. Within the new analyze, they assessed irrespective of whether or not vitamin C may in the identical method help to guard in opposition to doxorubicin’s hostile outcomes on skeletal muscle.
The researchers in distinction skeletal muscle mass mass and markers of oxidative stress in 4 groups of rats with eight to 10 animals in every group. One explicit group been given each equally vitamin C and doxorubicin, a subsequent group obtained solely vitamin C, a 3rd group acquired solely doxorubicin and a fourth group obtained neither. The mice that acquired vitamin C together with doxorubicin confirmed proof of diminished oxidative stress and higher muscle mass mass in comparison with mice that have been being specified doxorubicin however no vitamin C.
“It’s fascinating that the vitamin C prophylactic and concurrent therapy plans equipped for only a individual week proper earlier than and managed for another two weeks proper after using doxorubicin was sufficient to attenuate the facet results of this drug on skeletal muscle mass, contributing to a massively helpful results on the wellness of the researched animals,” said Nascimento Filho. “Our work demonstrated that vitamin C treatment can mitigate the decline in muscle mass mass and improve fairly just a few markers of free radicals’ imbalance in rats subjected to doxorubicin administration.”
The scientists famous that even additional evaluation, which embrace randomized scientific trials, can be essential to affirm no matter whether or not utilizing vitamin C throughout doxorubicin process can be helpful for human people, and to determine the proper dosage and timing. Previous scientific exams have steered vitamin C may intervene with the outcomes of chemotherapy medicines, so victims aren’t really useful to simply take vitamin C dietary supplements throughout most cancers therapy choices besides directed to take action by their medical skilled.
Nascimento Filho will present this research from 10:15 a.m.–12:15 p.m., Monday, April 4, in Exhibit/Poster Corridor A-B, Pennsylvania Conference Centre (Poster Board Quantity E277) (abstract). Converse to the media crew for lots extra particulars or to acquire a completely free push move to attend the meeting.
